Baker McKenzie Advises Highbridge Capital Management, LLC on its Additional CHF 10 Million Investment in Santhera Pharmaceuticals via Convertible Bond

In order to help Santhera Pharmaceuticals (SIX: SANN, “Santhera”) expand its global reach with AGAMREE® (vamorolone), a treatment for Duchenne muscular dystrophy, Baker McKenzie Switzerland advised certain funds managed by Highbridge Capital Management, LLC (“Highbridge”), a longtime investor in Santhera Pharmaceuticals, on its investment and commitment of an additional CHF 10 million via a new three-year convertible bond.